Fulcrum Therapeutics (FULC) EBIT (2018 - 2026)
Fulcrum Therapeutics (FULC) has 9 years of EBIT data on record, last reported at -$22.2 million in Q1 2026.
- On a quarterly basis, EBIT fell 8.74% to -$22.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$86.6 million, a 594.3% decrease, with the full-year FY2025 number at -$84.8 million, down 287.13% from a year prior.
- EBIT reached -$22.2 million in Q1 2026 per FULC's latest filing, up from -$22.7 million in the prior quarter.
- Over the last five years, EBIT for FULC hit a ceiling of $52.5 million in Q2 2024 and a floor of -$34.2 million in Q2 2022.
- A 5-year average of -$20.7 million and a median of -$25.1 million in 2024 define the central range for EBIT.
- Peak YoY movement for EBIT: soared 292.33% in 2024, then tumbled 137.75% in 2025.
- Tracing FULC's EBIT over 5 years: stood at -$28.0 million in 2022, then decreased by 0.07% to -$28.0 million in 2023, then soared by 30.59% to -$19.4 million in 2024, then fell by 16.8% to -$22.7 million in 2025, then rose by 2.23% to -$22.2 million in 2026.
- Business Quant data shows EBIT for FULC at -$22.2 million in Q1 2026, -$22.7 million in Q4 2025, and -$21.9 million in Q3 2025.